Browsing by Author "Anar C."

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    The effect of chemotherapy on quality of life in patients with lung carcinoma
    (Gulhane Medical School, University of Health Sciences, 2012) Anar C.; Altiparmak O.; Ünsal I.; Altiparmak S.; Tatar D.; Halilçolar H.
    The aim of the present study was to determine the effect of chemotherapy on the quality of life of patients with lung carcinoma. Fifty patients who were receiving chemotherapy between January 2006 and January 2007 were included in the study. The quality of life questionnaire (QLQ C-30), lung cancer specific module (LC-13) of the European Organization for Research and Treatment of Cancer (EORTC), and visual analog scale (VAS) were used in data collection. Chemotherapy resulted in worsening of social functioning, as well as dyspnea, constipation, and alopecia, whereas coughing improved. The economic status of the patients became worse compared to the first chemotherapy period (p<0.05). Chemotherapy led to a decrease in physical and social functioning in the patients with non-small cell lung cancer, and an increase in fatigue, nausea, insomnia, and constipation. No statistical significance was observed between the presence of metastases and quality of life. Pain negatively affected all subscales of the quality of life. Although no relationship was observed between the quality of life and sociodemographic characteristics, such as age and educational status, gender affected the quality of life, and the role, emotional, and cognitive functioning of the quality of life were worse in females compared to males. Sociodemographic characteristics had no significant impact on the quality of life of the patients with lung cancer. Pain negatively affected all areas of quality of life; indeed, the quality of life of the patients decreased as pain increased.
  • No Thumbnail Available
    Item
    A New Inflammatory Prognostic Index, Based on C-reactive Protein, the Neutrophil to Lymphocyte Ratio and Serum Albumin is Useful for Predicting Prognosis in Non-Small Cell Lung Cancer Cases
    (Asian Pacific Organization for Cancer Prevention, 2016) Dirican N.; Dirican A.; Anar C.; Atalay S.; Ozturk O.; Bircan A.; Akkaya A.; Cakir M.
    Purpose: We aimed to establish an inflammatory prognostic index (IPI) in early and advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze its predictive value for NSCLC survival. Materials and Methods: A retrospective review of 685 patients with early and advanced NSCLC diagnosed between 2009 and 2014 was conducted with collection of clinical, and laboratory data. The IPI was calculated as C-reactive protein × NLR (neutrophil/ lymphocyte ratio)/serum albumin. Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors. Results: The optimal cut-off value of IPI for overall survival (OS) stratification was determined to be 15. Totals of 334 (48.8%) and 351 (51.2%) patients were assigned to high and low IPI groups, respectively. Compared with low IPI, high IPI was associated with older age, greater tumor size, high lymph node involvement, distant metastases, advanced stage and poor performance status. Median OS was worse in the high IPI group (low vs high, 8.0 vs 34.0 months; HR, 3.5; p<0.001). Progression free survival values of the patients who had high vs low IPI were determined 6 months (95% CI:5.3-6.6) and 14 months (95% CI:12.1-15.8), respectively (HR; 2.4, P<0.001). On multivariate analysis, stage, performance status, lactate dehydrogenase and IPI were independent prognostic factors for OS. Subgroup analysis showed IPI was generally a significant prognostic factor in all clinical variables. Conclusion: The described IPI may be an inexpensive, easily accessible and independent prognostic index for NSCLC patients, useful for clinical practice. © 2016, Asian Pacific Journal of Cancer Prevention. All Rights Reserved.
  • No Thumbnail Available
    Item
    A new inflammatory prognostic index, based on C-reactive protein, the neutrophil to lymphocyte ratio and serum albumin is useful for predicting prognosis in non-small cell lung cancer cases
    (Asian Pacific Organization for Cancer Prevention, 2016) Dirican N.; Dirican A.; Anar C.; Atalay S.; Ozturk O.; Bircan A.; Akkaya A.; Cakir M.
    Purpose: We aimed to establish an inflammatory prognostic index (IPI) in early and advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze its predictive value for NSCLC survival. Materials and Methods: A retrospective review of 685 patients with early and advanced NSCLC diagnosed between 2009 and 2014 was conducted with collection of clinical, and laboratory data. The IPI was calculated as C-reactive protein × NLR (neutrophil/ lymphocyte ratio)/serum albumin. Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors. Results: The optimal cut-off value of IPI for overall survival (OS) stratification was determined to be 15. Totals of 334 (48.8%) and 351 (51.2%) patients were assigned to high and low IPI groups, respectively. Compared with low IPI, high IPI was associated with older age, greater tumor size, high lymph node involvement, distant metastases, advanced stage and poor performance status. Median OS was worse in the high IPI group (low vs high, 8.0 vs 34.0 months; HR, 3.5; p < 0.001). Progression free survival values of the patients who had high vs low IPI were determined 6 months (95% CI:5.3-6.6) and 14 months (95% CI:12.1-15.8), respectively (HR; 2.4, P < 0.001). On multivariate analysis, stage, performance status, lactate dehydrogenase and IPI were independent prognostic factors for OS. Subgroup analysis showed IPI was generally a significant prognostic factor in all clinical variables. Conclusion: The described IPI may be an inexpensive, easily accessible and independent prognostic index for NSCLC patients, useful for clinical practice.
  • No Thumbnail Available
    Item
    Short-acting β2-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III
    (BioMed Central Ltd, 2022) Yorgancıoğlu A.; Aksu K.; Naycı S.A.; Ediger D.; Mungan D.; Gül U.; Beekman M.J.H.I.; Kızılırmak D.; Altıntaş N.; Bulut İ.; Çağatay T.; Gemicioğlu B.; İnce Ö.; Oğuzülgen K.; Kalpaklıoğlu F.; Baççıoğlu A.; Aksu F.; Altuntaş M.; Erkekol F.Ö.; Karakaya G.; Kalyoncu A.F.; Damadoğlu E.; Hanta İ.; Altunok E.; Özer A.; Yuluğ D.P.; Gülbaş G.; Süerdem M.; Yormaz B.; Ceylan E.; Erge D.; Çilli A.; Doğan B.C.; Erel F.; Sevinç C.; Anar C.; Pekbak G.; Erbay M.
    Background: Over-reliance on short-acting β2-agonists (SABAs) is associated with poor asthma outcomes. However, the extent of SABA use in Turkey is unclear owing to a lack of comprehensive healthcare databases. Here, we describe the demographics, disease characteristics and treatment patterns from the Turkish cohort of the SABA use IN Asthma (SABINA) III study. Methods: This observational, cross-sectional study included patients aged ≥ 12 years with asthma from 24 centres across Turkey. Data on sociodemographics, disease characteristics and asthma treatments were collected using electronic case report forms. Patients were classified by investigator-defined asthma severity (guided by the 2017 Global Initiative for Asthma [GINA]) and practice type (primary/specialist care). The primary objective was to describe SABA prescription patterns in the 12 months prior to the study visit. Results: Overall, 579 patients were included (mean age [standard deviation; SD]: 47.4 [16.1] years; 74.3% female), all of whom were treated by specialists. Most patients had moderate-to-severe asthma (82.7%, GINA steps 3–5), were overweight or obese (70.5%), had high school or university/post-graduate education (51.8%) and reported fully reimbursed healthcare (97.1%). The mean (SD) asthma duration was 12.0 (9.9) years. Asthma was partly controlled/uncontrolled in 56.3% of patients, and 46.5% experienced ≥ 1 severe exacerbation in the preceding 12 months. Overall, 23.9% of patients were prescribed ≥ 3 SABA canisters in the previous 12 months (considered over-prescription); 42.9% received no SABA prescriptions. As few patients had mild asthma, only 5.7% were prescribed SABA monotherapy. Therefore, most patients (61.5%) were prescribed SABA in addition to maintenance therapy, with 42.8% receiving ≥ 3 SABA canisters in the previous 12 months. Inhaled corticosteroids (ICS), ICS + a long-acting β-agonist fixed-dose combination and oral corticosteroids were prescribed to 14.5%, 88.3% and 28.5% of all patients, respectively. Additionally, 10.2% of patients purchased SABA over the counter, of whom 27.1% purchased ≥ 3 canisters in the preceding 12 months. Conclusions: Despite all patients being treated by specialists and most receiving fully reimbursed healthcare, nearly a quarter of patients received prescriptions for ≥ 3 SABA canisters in the previous 12 months. This highlights a public health concern and emphasizes the need to align clinical practices with the latest evidence-based recommendations. © 2022, The Author(s).
  • No Thumbnail Available
    Item
    Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a cost analysis with respect to the updated GINA treatment recommendations
    (BioMed Central Ltd, 2024) Yorgancıoğlu A.; Aksu K.; Cura C.; Yaman Y.; Dinç M.; Malhan S.; Erbay M.; Pekbak G.; Ediger D.; Anar C.; Sevinç C.; Erel F.; Doğan B.C.; Çilli A.; Erge D.; Ceylan E.; Yormaz B.; Süerdem M.; Gülbaş G.; Yuluğ D.P.; Naycı S.A.; Özer A.; Altunok E.; Hanta İ.; Damadoğlu E.; Kalyoncu A.F.; Karakaya G.; Erkekol F.Ö.; Altuntaş M.; Aksu F.; Baççıoğlu A.; Kalpaklıoğlu F.; Mungan D.; Oğuzülgen K.; İnce Ö.; Gemicioğlu B.; Çağatay T.; Bulut İ.; Altıntaş N.; Kızılırmak D.
    Background: This cost of illness study aimed to determine economic burden of short-acting β2-agonist (SABA) overuse in Türkiye from payer perspective with respect to the updated GINA 2022 treatment recommendations. Methods: A total of 3,034,879 asthma patients comprised the study population, via estimations extrapolated from the Türkiye arm of the global SABINA III study. The economic burden (costs related to the drug use and severe exacerbations) was compared in subgroups of overall (≥ 0 canisters/year) vs. GINA-recommended (0–2 canisters/year, hypothetical population) SABA use and in subgroups of appropriate use (0–2 canisters/year, real population) vs. overuse (≥ 3 canisters/year) of SABA with extrapolation of SABINA Türkiye data to the Türkiye asthma population. Results: Recommended SABA use was predicted to prevent 127,505 of 157,512 severe exacerbations per year in mild asthma patients and 2,668,916 of 3,262,800 severe exacerbations per year in moderate-severe asthma patients. Annual cost burden of not applying recommended SABA use (overall [≥ 0 canisters/year] vs. GINA-recommended [0–2 canisters/year] SABA use) in mild asthma and moderate-severe asthma patients was calculated to be €20.43 million and €427.65 million in terms of severe exacerbations, and to be €829,352 and €7.20 million in terms of drug costs, respectively. The total annual economic burden arising from not applying recommended SABA use was estimated to be €456.11 million. Appropriate use (0–2 canisters/year) vs. overuse (≥ 3 canisters/year) of SABA was associated with decreased frequency of severe exacerbations per year in mild asthma (from 129,878 to 27,634) and moderate-severe asthma (from 2,834,611 to 428,189) patients. SABA overuse in mild and moderate-severe asthma patients was estimated to yield an additional annual cost of €16.38 million and €385.59 million, respectively in terms of severe exacerbations, and a total €11.30 million additional drug cost. The overall annual economic burden arising from SABA overuse was estimated to be €413.27 million. Conclusions: The estimated annual total economic burden arising from not applying recommended SABA use (€456.11 million) and SABA overuse (€413.27 million) with respect to the updated GINA 2022 treatment recommendations indicates the substantial cost burden of SABA overuse to the Turkish National Health System, corresponding up to 26% of the total direct cost of asthma reported in our country. © The Author(s) 2024.